MFS Medifocus Inc

In the news release, "Cohen Independent Research Initiates Coverage on Medifocus
Inc. With a Strong Buy Recommendation," issued earlier today by Cohen
Independent Research Group Inc., we are advised by the company that some words
have been altered in the first sentence of the second paragraph. "Prostate
Cancer treatment system" has been changed to "enlarged Prostate (BPH) heat
treatment system." In addition, a new third paragraph has been added. Complete
corrected text follows.


Cohen Independent Research Initiates Coverage on Medifocus Inc. With a Strong
Buy Recommendation


12-Month Price Target of $.74 per Share

SAN RAFAEL, CA -- October 10, 2012 -- Cohen Independent Research (CIR), Wall
Street's leading independent micro-cap research firm, has announced that it has
initiated coverage on Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) with a
STRONG BUY recommendation and a 12-month price target of $.74 per share. CIR
provides an in-depth analysis, including 5-year financial and valuation
projections, on Medifocus' business and its significant growth drivers. A copy
of the report is available for download at www.cohenresearch.com.


An excerpt from the report states, "Medifocus has already commercialized its
enlarged Prostate (BPH) heat treatment system, 'The Prolieve(R),' which was
developed by the Company's scientific team. Medifocus plans to generate revenue
between $40 million to $60 million from the sale of The Prolieve(R) in the next
few years."


The Company also has an advanced medical system utlilizing the Company's
Adaptive Phased Array Radar Technology (APA)-1000 for treatment of Breast
Cancer. The APA-1000 uses focused and controlled microwave energy to shrink or
eradicate cancerous tumours with minimal invasion and better outcomes. It is
currently in the advanced phase-III clinical trial and will address the $4
billion dollar Breast Cancer treatment market.


About Cohen Independent Research
Cohen Independent Research is Wall Street's leading independent micro-cap
research firm, concentrating on emerging companies with strong management teams
focused on shareholder value and sustainable competitive advantage. CIR, led by
renowned security analyst, Paul Cohen, this CFA analyst written research report
highlight the company's market opportunity, technology, management, competition
and other key differentiators that may affect their long- and short-term
valuation. CIR focuses on those public companies that lack or have minimal Wall
Street research analyst coverage. CIR research reports are commissioned and paid
for by the companies covered, or by third parties. For more information, visit:
www.cohenresearch.com.


This report/release is for informational purposes only. All information
contained herein is based on public information. Cohen Independent Research
Group, Inc. (CIR) complies with securities laws, regulations and ethical
standards as related to our legal and compliance requirements. Certain
securities regulations are cited and disclaimed in our Disclaimer. Ethical
standards as related to our firm are the foundation of those securities laws and
regulations we follow. Our firm is not a member of any association for other
research providers. Our firm's policy is to comply with any new securities laws
and regulations that might be promulgated in the future. CIR is not a registered
investment advisor that distributes contracted third party independent research
purchased from outside third party contracted securities analysts. To access the
complete disclosure and disclaimer, download a copy of the Medifocus Inc. report
at www.cohenresearch.com.


About Medifocus

Medifocus owns a patented microwave focusing technology platform (the Adaptive
Phased Array ("APA") technology), which can precisely target and control
microwave energy to cause heating in cancerous tumors anywhere in the body
reliably and repeatedly. The ability to target tumors with a precision
controlled dose of heat can be used to destroy tumors at higher temperatures, to
treat tumors in combination with chemotherapy and/or radiation at moderate
temperatures for increased effectiveness and reduced toxicity and to trigger the
targeted release of therapeutic drugs and genes at tumor sites at lower
temperatures. While the core technology has been licensed from the Massachusetts
Institute of Technology, Medifocus has further refined the precision of the
microwave focusing and control ability and developed a commercial system
dedicated exclusively for the treatment of Breast Cancer. With the acquisition
of Prolieve(R), Medifocus now owns in addition, a revenue generating commercial
BPH heat treatment product generating cash flow to support the development and
commercialization of other catheter based or APA based external focused heat
systems for targeted thermotherapy of deep seated tumors anywhere in the body.
Please visit www.medifocusinc.com for more details.


Safe Harbor Statement: The Private Securities Litigation Reform Act of 1995
provides a "Safe harbor" for forward-looking statements. Certain of the
statements contained herein, which are not historical facts, are forward-looking
statements with respect to events, the occurrence of which involved risks and
uncertainties. These forward-looking statements may be impacted, either
positively or negatively, by various factors. Information concerning potential
factors that could affect the company is detailed from time to time in the
company's reports filed with the Securities and Exchange Commission.

Grafico Azioni Medifocus (TSXV:MFS)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Medifocus (TSXV:MFS)
Storico
Da Giu 2023 a Giu 2024